Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Catheterization and Cardiovascular Interventions

Volumn 58, Issue 1, 2003, Pages 65-68

  Pinto, Duane S ^a   Sperling, Robert T ^a   Tu, Thomas M ^a   Cohen, David J ^a   Carrozza Jr , Joseph P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Heparin induced thrombocytopenia; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LEPIRUDIN; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULANT THERAPY; ARTICLE; ATHERECTOMY; BRACHYTHERAPY; CORONARY ARTERY; CORONARY ARTERY THROMBOSIS; DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; MORBIDITY; MORTALITY; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; THROMBECTOMY; THROMBOCYTE; THROMBOCYTOPENIA; TRANSFUSION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TYROSINE;

EID: 0037223078     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10393     Document Type: Article

References (21)

1. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
2. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-1459.
3. Warkentin TE. Heparin-induced thrombocytopenia: A ten-year retrospective. Ann Rev Med 1999;50:129-147.
4. Matthai WH Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25:57-60.
5. Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, Califf RM. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12:14F-19F.
6. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia study (HAT) investigators. Circulation 1999;100:587-593.
7. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80.
8. Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina: Hirulog Angioplasty Study investigators. Am J Cardiol 1998;82:43P-49P.
9. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
10. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995;333:757-763.
11. EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
12. ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
13. Kleiman NS, Lincoff AM, Sapp SK, et al. Pharmacodynamics of a direct thrombin inhibitor combined with GP IIb/IIIa antagonist: First experience in humans. Circulation 1999;100(Suppl):1328.
14. Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: Genesis of the comparison of abciximab complications with hirulog (and back-up abciximab) events trial (CACHET). Am J Cardiol 1998;82:63P-68P.
15. Caputo RP, Giambartolomei A, Simons A, Reger M, Wagner S, Esente P. Adjunctive therapies in the cath lab: Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia. J Invas Cardiol 2001;13:657-660.
16. Walenga JM, Jeske WP, Wallis DE, Bakhos M, Lewis BE, Leya F, Fareed J. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999;25:77-81.
17. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports. Cathet Cardiovasc Intervent 2001;52:468-472.
18. Laubenthal FC, Grosch B, Szurawitzki G, Sabin GV. Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA-treatment with lepirudin (Refludan) and abciximab (Reopro) during recanalization of the RCA. Z Kardiol 1999;88:141-146.
19. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
20. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-874.
21. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA. Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.